• +1-646-491-9876
    • +91-20-67278686

    Search

    Glomerulonephritis - Pipeline Review, H1 2017

    Glomerulonephritis - Pipeline Review, H1 2017

    • Report Code ID: RW0001767484
    • Category Pharmaceuticals
    • No. of Pages 137
    • Publication Month Apr-17
    • Publisher Name Global Markets Direct
    Glomerulonephritis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Glomerulonephritis - Pipeline Review, H1 2017, provides an overview of the Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline landscape.

    Glomerulonephritis is also known as glomerular nephritis (GN) or glomerular disease. It is a disease of the kidney, characterized by inflammation of the glomeruli. Causes of glomerulonephritis include Streptococcal infection of the throat known as strep throat, immune diseases, such as lupus, Type 1 diabetes and type 2 diabetes and viruses, such as HIV, hepatitis B virus, and hepatitis C virus. Factors that increase chances of getting glomerulonephritis include family history of glomerulonephritis, the presence of a known cause of glomerulonephritis and high blood pressure. Common symptoms of glomerulonephritis are blood in the urine (dark, rust-colored, or brown urine) , foamy urine, swelling (edema) of the face, eyes, ankles, feet, legs, or abdomen. Treatment will depend on the cause of glomerulonephritis such as medications, lifestyle changes, dialysis and transplant.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Glomerulonephritis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 8, 2, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

    Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Glomerulonephritis (Genito Urinary System And Sex Hormones) .
    - The pipeline guide reviews pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Glomerulonephritis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Glomerulonephritis (Genito Urinary System And Sex Hormones)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Glomerulonephritis (Genito Urinary System And Sex Hormones) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Glomerulonephritis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Glomerulonephritis - Overview
    Glomerulonephritis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Glomerulonephritis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Glomerulonephritis - Companies Involved in Therapeutics Development
    Achillion Pharmaceuticals Inc
    Alexion Pharmaceuticals Inc
    Anthera Pharmaceuticals Inc
    Biogen Inc
    BLR Bio LLC
    ChemoCentryx Inc
    Dimerix Bioscience Pty Ltd
    GlaxoSmithKline Plc
    Mallinckrodt Plc
    Omeros Corp
    Pfizer Inc
    Pharmalink AB
    Ra Pharmaceuticals Inc
    Retrophin Inc
    Rigel Pharmaceuticals Inc
    Shire Plc
    Visterra Inc
    Glomerulonephritis - Drug Profiles
    (irbesartan + propagermanium) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ACH-4471 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMY-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AVX-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BaxB-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BaxG-03 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    belimumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    blisibimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BLR-400 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    budesonide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CCX-140 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    corticotropin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fostamatinib disodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    losmapimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit ITGAM for Cardiovascular, Immunology and Kidney Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OMS-721 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-1355 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Enzyme for Immunoglobulin A Nephropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SHP-627 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Factor D for PNH and Dense Deposit Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Factor D for Paroxysmal Nocturnal Hemoglobinuria and Membranoproliferative Glomerulonephritis Type II - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sparsentan - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides to Inhibit Factor D for Age-Related Macular Degeneration, Paroxysmal Nocturnal Hemoglobinuria and Renal Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TM-5484 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target CD40 for Membranous Glomerulonephritis - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VAR-200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VIS-649 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Glomerulonephritis - Dormant Projects
    Glomerulonephritis - Discontinued Products
    Glomerulonephritis - Product Development Milestones
    Featured News & Press Releases
    Mar 01, 2017: Retrophin Provides Sparsentan Regulatory Update
    Feb 28, 2017: Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal Disorder, Conducted by Experts at Imperial College London
    Jan 09, 2017: ChemoCentryx Provides Update on Lead Program CCX140
    Nov 30, 2016: World Renowned Experts Join Variant Pharmaceuticals' Scientific Advisory Board
    Nov 21, 2016: Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
    Nov 19, 2016: Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016
    Oct 21, 2016: Retrophin to Present Additional Data from Phase 2 DUET Study of Sparsentan in Late-Breaking Oral Session at ASN Kidney Week 2016
    Sep 07, 2016: Retrophin Announces Positive Top-Line Results from Phase 2 DUET Study of Sparsentan in Patients with Focal Segmental Glomerulosclerosis
    Aug 01, 2016: Dimerix announces outcomes of DMX-200 pre-IND meeting with the FDA
    May 17, 2016: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel for Rare Cause of Nephrotic Syndrome
    Mar 30, 2016: Retrophin Completes Enrollment of Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis
    Mar 04, 2016: Amyndas' lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy
    Dec 14, 2015: Dimerix receives Orphan Designation for its lead drug candidate targeting patients with chronic kidney disease
    Nov 16, 2015: Retrophin Receives European Orphan Drug Designation for Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis
    Jan 09, 2015: Ligand Partner Retrophin Receives Orphan Drug Designation for Sparsentan
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Glomerulonephritis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Glomerulonephritis - Pipeline by Achillion Pharmaceuticals Inc, H1 2017
    Glomerulonephritis - Pipeline by Alexion Pharmaceuticals Inc, H1 2017
    Glomerulonephritis - Pipeline by Anthera Pharmaceuticals Inc, H1 2017
    Glomerulonephritis - Pipeline by Biogen Inc, H1 2017
    Glomerulonephritis - Pipeline by BLR Bio LLC, H1 2017
    Glomerulonephritis - Pipeline by ChemoCentryx Inc, H1 2017
    Glomerulonephritis - Pipeline by Dimerix Bioscience Pty Ltd, H1 2017
    Glomerulonephritis - Pipeline by GlaxoSmithKline Plc, H1 2017
    Glomerulonephritis - Pipeline by Mallinckrodt Plc, H1 2017
    Glomerulonephritis - Pipeline by Omeros Corp, H1 2017
    Glomerulonephritis - Pipeline by Pfizer Inc, H1 2017
    Glomerulonephritis - Pipeline by Pharmalink AB, H1 2017
    Glomerulonephritis - Pipeline by Ra Pharmaceuticals Inc, H1 2017
    Glomerulonephritis - Pipeline by Retrophin Inc, H1 2017
    Glomerulonephritis - Pipeline by Rigel Pharmaceuticals Inc, H1 2017
    Glomerulonephritis - Pipeline by Shire Plc, H1 2017
    Glomerulonephritis - Pipeline by Visterra Inc, H1 2017
    Glomerulonephritis - Dormant Projects, H1 2017
    Glomerulonephritis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Glomerulonephritis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Achillion Pharmaceuticals Inc
    Alexion Pharmaceuticals Inc
    Anthera Pharmaceuticals Inc
    Biogen Inc
    BLR Bio LLC
    ChemoCentryx Inc
    Dimerix Bioscience Pty Ltd
    GlaxoSmithKline Plc
    Mallinckrodt Plc
    Omeros Corp
    Pfizer Inc
    Pharmalink AB
    Ra Pharmaceuticals Inc
    Retrophin Inc
    Rigel Pharmaceuticals Inc
    Shire Plc
    Visterra Inc

    Request for Sample

    Report Url http://www.reportsweb.com//glomerulonephritis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//glomerulonephritis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//glomerulonephritis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments